Agilent Technologies (NYSE:A) Stock Rating Lowered by UBS Group

UBS Group lowered shares of Agilent Technologies (NYSE:AFree Report) from a buy rating to a neutral rating in a report released on Friday, Marketbeat.com reports. They currently have $125.00 price objective on the medical research company’s stock, down from their previous price objective of $163.00.

Other analysts also recently issued research reports about the stock. Barclays cut their price objective on shares of Agilent Technologies from $110.00 to $105.00 and set an underweight rating for the company in a report on Friday, September 29th. Evercore ISI dropped their target price on shares of Agilent Technologies from $124.00 to $120.00 and set an in-line rating for the company in a research report on Wednesday, August 16th. Sanford C. Bernstein started coverage on shares of Agilent Technologies in a research note on Thursday, September 28th. They issued a market perform rating and a $123.00 price objective on the stock. Credit Suisse Group cut their target price on Agilent Technologies from $160.00 to $150.00 and set an outperform rating for the company in a research note on Wednesday, August 16th. Finally, JPMorgan Chase & Co. decreased their price target on Agilent Technologies from $155.00 to $150.00 and set an overweight rating on the stock in a research note on Wednesday, August 16th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, Agilent Technologies has a consensus rating of Moderate Buy and a consensus price target of $143.94.

Get Our Latest Analysis on Agilent Technologies

Agilent Technologies Price Performance

Shares of A opened at $113.98 on Friday. The company’s fifty day simple moving average is $109.98 and its 200 day simple moving average is $117.66. Agilent Technologies has a 1-year low of $96.80 and a 1-year high of $160.26. The company has a market cap of $33.35 billion, a price-to-earnings ratio of 29.84, a PEG ratio of 2.01 and a beta of 1.04. The company has a current ratio of 2.29, a quick ratio of 1.68 and a debt-to-equity ratio of 0.49.

Agilent Technologies (NYSE:AGet Free Report) last released its quarterly earnings results on Monday, November 20th. The medical research company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.04. The firm had revenue of $1.69 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 16.20% and a return on equity of 29.86%. The business’s revenue was down 8.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.53 EPS. On average, research analysts forecast that Agilent Technologies will post 5.41 earnings per share for the current fiscal year.

Agilent Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 24th. Shareholders of record on Tuesday, January 2nd will be issued a dividend of $0.236 per share. This represents a $0.94 dividend on an annualized basis and a yield of 0.83%. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.23. The ex-dividend date of this dividend is Friday, December 29th. Agilent Technologies’s payout ratio is presently 24.61%.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, VP Rodney Gonsalves sold 3,500 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $118.78, for a total value of $415,730.00. Following the sale, the vice president now owns 24,219 shares in the company, valued at approximately $2,876,732.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of A. Bank Julius Baer & Co. Ltd Zurich grew its stake in Agilent Technologies by 13,422.2% during the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 37,574,064 shares of the medical research company’s stock worth $4,518,281,000 after purchasing an additional 37,296,195 shares during the period. BlackRock Inc. increased its stake in shares of Agilent Technologies by 1.1% in the 2nd quarter. BlackRock Inc. now owns 31,853,176 shares of the medical research company’s stock valued at $3,830,344,000 after acquiring an additional 349,651 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Agilent Technologies by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 24,531,170 shares of the medical research company’s stock valued at $3,246,209,000 after acquiring an additional 261,435 shares in the last quarter. State Street Corp lifted its position in shares of Agilent Technologies by 2.0% during the 2nd quarter. State Street Corp now owns 13,214,595 shares of the medical research company’s stock valued at $1,591,990,000 after acquiring an additional 253,729 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its stake in Agilent Technologies by 0.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 11,076,270 shares of the medical research company’s stock worth $1,238,549,000 after acquiring an additional 39,030 shares in the last quarter. Institutional investors and hedge funds own 85.42% of the company’s stock.

About Agilent Technologies

(Get Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.

Recommended Stories

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.